AtriCure, Inc. (ATRC) Stake Lowered by Victory Capital Management Inc.

Victory Capital Management Inc. reduced its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 22.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,028,345 shares of the medical device company’s stock after selling 291,130 shares during the quarter. Victory Capital Management Inc. owned approximately 3.00% of AtriCure worth $23,004,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. FMR LLC boosted its holdings in shares of AtriCure by 2.4% in the 2nd quarter. FMR LLC now owns 5,068,247 shares of the medical device company’s stock worth $122,905,000 after acquiring an additional 118,247 shares in the last quarter. Vanguard Group Inc. raised its position in AtriCure by 3.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,446,732 shares of the medical device company’s stock worth $35,083,000 after purchasing an additional 52,761 shares during the last quarter. First Light Asset Management LLC raised its position in AtriCure by 0.3% in the 2nd quarter. First Light Asset Management LLC now owns 958,858 shares of the medical device company’s stock worth $23,252,000 after purchasing an additional 2,400 shares during the last quarter. Peregrine Capital Management LLC raised its position in AtriCure by 3.5% in the 3rd quarter. Peregrine Capital Management LLC now owns 924,740 shares of the medical device company’s stock worth $20,686,000 after purchasing an additional 31,526 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its position in AtriCure by 45.5% in the 2nd quarter. Neuberger Berman Group LLC now owns 824,469 shares of the medical device company’s stock worth $19,993,000 after purchasing an additional 257,949 shares during the last quarter. 81.34% of the stock is currently owned by institutional investors and hedge funds.

In other AtriCure news, Director B Kristine Johnson bought 1,500 shares of the company’s stock in a transaction on Wednesday, November 8th. The stock was bought at an average price of $18.36 per share, for a total transaction of $27,540.00. Following the transaction, the director now owns 10,969 shares of the company’s stock, valued at approximately $201,390.84. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Elizabeth D. Krell sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $22.40, for a total transaction of $224,000.00. Following the sale, the director now owns 29,967 shares of the company’s stock, valued at approximately $671,260.80. The disclosure for this sale can be found here. Insiders own 10.00% of the company’s stock.

ATRC has been the subject of several research analyst reports. Stifel Nicolaus restated a “buy” rating and issued a $25.00 price objective on shares of AtriCure in a research report on Sunday, July 30th. Needham & Company LLC restated a “buy” rating and issued a $26.00 price objective (up previously from $25.00) on shares of AtriCure in a research report on Friday, July 28th. BidaskClub cut shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Canaccord Genuity dropped their price objective on shares of AtriCure from $28.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, November 2nd. Finally, Zacks Investment Research upgraded shares of AtriCure from a “sell” rating to a “hold” rating in a research report on Monday, October 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $25.00.

Shares of AtriCure, Inc. (NASDAQ ATRC) opened at $18.60 on Friday. AtriCure, Inc. has a 1 year low of $14.78 and a 1 year high of $25.18. The company has a current ratio of 2.28, a quick ratio of 1.65 and a debt-to-equity ratio of 0.20.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Wednesday, November 1st. The medical device company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.02. The company had revenue of $42.20 million during the quarter, compared to analysts’ expectations of $43.44 million. AtriCure had a negative net margin of 19.40% and a negative return on equity of 20.28%. The business’s revenue for the quarter was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.21) EPS. equities research analysts forecast that AtriCure, Inc. will post -0.96 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “AtriCure, Inc. (ATRC) Stake Lowered by Victory Capital Management Inc.” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://stocknewstimes.com/2017/11/11/atricure-inc-atrc-stake-lowered-by-victory-capital-management-inc.html.

AtriCure Profile

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC).

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply